Business Context and Reporting Period
Zevra Therapeutics, Inc. (ZVRA) is a commercial-stage biopharmaceutical company focused on rare diseases. This Form 10-K covers the fiscal year ended December 31, 2024. The company operates as a single reporting segment. Key strategic developments in 2024 included the FDA approval of MIPLYFFA (arimoclomol) for Niemann-Pick disease type C (NPC) in September 2024 and its subsequent commercial launch in November 2024. The company also continues to commercialize OLPRUVA for urea cycle disorders (UCDs) and advance clinical development for celiprolol (VEDS) and KP1077 (Idiopathic Hypersomnia). In February 2025, the company entered an agreement to sell the Priority Review Voucher (PRV) received with MIPLYFFA approval for $150 million.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue (Net) | $23.6 million | $27.5 million |
| Net Loss | $(105.5) million | $(46.0) million |
| Loss from Operations | $(87.0) million | $(49.6) million |
| Operating Expenses | $97.0 million | $74.1 million |
| Research & Development | $42.1 million | $39.8 million |
| Selling, General & Administrative | $54.9 million | $34.3 million |
| Cash, Cash Equivalents & Investments | $75.5 million | $67.7 million |
| Long-Term Debt | $59.5 million | $5.1 million |
| Net Cash Used in Operating Activities | $(69.7) million | $(33.5) million |
Note: The filing text does not provide explicit gross margin percentages. Cost of product revenue was $7.4 million in 2024, including $5.7 million in inventory obsolescence related to OLPRUVA.
Material Changes vs. Prior Period
- Revenue Decline: Net revenue decreased by $3.8 million (14%) primarily due to a $14.2 million decrease in revenue from the AZSTARYS License Agreement (royalties and milestones). This was partially offset by $10.1 million in new MIPLYFFA product sales.
- Increased Net Loss: Net loss more than doubled to $105.5 million, driven by a $37.4 million increase in operating loss, a $15.4 million income tax expense (due to periodic evaluation of tax positions), and increased interest expense.
- Expense Growth: SG&A expenses increased by $20.6 million, largely due to marketing costs ($10.1 million) and stock-based compensation ($7.2 million) associated with the commercial launch of MIPLYFFA and OLPRUVA.
- Debt Financing: Long-term debt increased significantly to $59.5 million following a new $100 million credit facility entered in April 2024, used to refinance existing indebtedness and fund operations.
- Inventory Write-down: The company recognized a $5.7 million charge for OLPRUVA inventory obsolescence in 2024.
Guidance, Outlook, and Risks
Outlook and Liquidity: Management believes existing cash, cash equivalents, and investments ($75.5 million as of Dec 31, 2024) are sufficient to fund operations into 2029, excluding the anticipated $150 million proceeds from the PRV sale. The company expects to continue incurring significant expenses and operating losses as it advances clinical trials and commercializes products.
Key Risks and Contingencies:
- Commercialization Risk: Success depends on market acceptance of MIPLYFFA and OLPRUVA in small patient populations. The company faces competition from AQNEURSA (NPC) and RAVICTI/PHEBURANE (UCDs).
- Regulatory Risk: Future approvals for celiprolol and KP1077 are uncertain. The company relies on the 505(b)(2) pathway for some candidates, which carries patent litigation risks.
- Legal Proceedings: The company is engaged in a legal dispute regarding the AZSTARYS License Agreement (initiated September 2024). While the agreement remains in effect, the outcome is uncertain and could impact future royalty revenue.
- Going Concern: The company has a history of negative operating cash flows and may require additional financing if commercialization targets are not met.
Investor Verification Checklist
- PRV Sale Closing: Verify the closing of the $150 million Priority Review Voucher sale announced in February 2025 and the timing of cash receipt.
- MIPLYFFA Commercialization: Monitor patient enrollment numbers and revenue growth rates for MIPLYFFA following its November 2024 launch.
- AZSTARYS Litigation: Track developments in the legal dispute regarding the AZSTARYS License Agreement and its potential impact on royalty streams.
- Debt Covenants: Review compliance with the new $100 million credit facility covenants, specifically minimum net product sales requirements.
- OLPRUVA Inventory: Assess future inventory levels and potential for additional write-downs given the $5.7 million charge in 2024.
- Cash Runway: Re-evaluate the "into 2029" liquidity estimate based on actual burn rates and revenue performance in 2025.